Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Biweekly Gemcitabine-Oxaliplatin and Dexamethasone for Relapsed/Refractory Malignant Lymphoma

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified November 2007 by Cooperative Study Group A for Hematology.
Recruitment status was:  Recruiting
Sponsor:
Information provided by:
Cooperative Study Group A for Hematology
ClinicalTrials.gov Identifier:
NCT00561301
First received: November 18, 2007
Last updated: NA
Last verified: November 2007
History: No changes posted

November 18, 2007
November 18, 2007
November 2006
Not Provided
objective response rate [ Time Frame: 10/2009 ]
Same as current
No Changes Posted
toxicities, progression-free survival, overall survival, ASCC efficacy, rate for proceeding to ASCT [ Time Frame: 10/2009 ]
Same as current
Not Provided
Not Provided
 
Biweekly Gemcitabine-Oxaliplatin and Dexamethasone for Relapsed/Refractory Malignant Lymphoma
Biweekly Gemcitabine-Oxaliplatin and Dexamethasone for Relapsed/Refractory Malignant Lymphoma
- To evaluate the feasibility of combination chemotherapies comprising of gemcitabine-dexamethasone-oxaliplatin for patients with refractory or relapsed malignant non-Hodgkin lymphoma (NHL)
- The feasibility will be evaluated in terms of objective response rate, efficacy of stem cell collection, disease-free survival, and overall survival.
Interventional
Phase 2
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Lymphoma
Drug: GemDOx
gemcitabine oxliplatin
No Intervention: 1
Intervention: Drug: GemDOx
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
43
October 2009
Not Provided

Inclusion Criteria:

  • Patients who have refractory to first-line CHOP-like regimen
  • Patients who have first relapse after
  • first-line CHOP-like regimen
  • upfront autologous or allogeneic hematopoietic stem cell transplantation
  • Age 15 years or more
  • ECOG performance status ≤ 2
  • Adequate bone marrow function
  • Adequate kidney,liver,cardiac

Exclusion Criteria:

  • Patients who have received GEM or OX
Both
15 Years to 65 Years   (Child, Adult)
No
Contact information is only displayed when the study is recruiting subjects
Korea, Republic of
 
NCT00561301
C-012A
No
Not Provided
Not Provided
Not Provided
Cooperative Study Group A for Hematology
Not Provided
Principal Investigator: Hawk Kim, professor Ulsan Universtity Hospital, ROK
Cooperative Study Group A for Hematology
November 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP